Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.

ABSTRACT: The effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) are unknown. In this pilot study we determined the effects of empagliflozin 10 mg/d for 4 weeks on peak oxygen consumption (VO₂ ) in 15 patients with T2DM and HFrEF. As an exploratory analysis, we assessed whether there was an interaction of the effects of empagliflozin on peak VO₂ of loop diuretics. Empagliflozin reduced body weight (-1.7 kg; P = .031), but did not change peak VO₂ (from 14.5 mL kg^-1 min^-1 [12.6-17.8] to 15.8 [12.5-17.4] mL kg^-1 min^-1 ; P = .95). However, patients using loop diuretics (N = 9) demonstrated an improvement, whereas those w

SUBMITTER: Carbone S 

PROVIDER: S-EPMC6043379 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature